Seroprevalence studies of pertussis: What have we learned from different immunized populations

Pathogens and Disease

Volumn 73, Issue 7, 2020, Pages

  Barkoff, Alex Mikael ^a   Gröndahl Yli Hannuksela, Kirsi ^a   He, Qiushui ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

ELISA; Pertussis; PT; Seroprevalence; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; PERTUSSIS ANTIBODY; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; COMPARATIVE STUDY; CONTROL STRATEGY; DISEASE BURDEN; HISTORY; HUMAN; INCIDENCE; INFECTION CONTROL; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SEROEPIDEMIOLOGY; SEROPREVALENCE; VACCINATION; VACCINATION COVERAGE; BORDETELLA PERTUSSIS; EPIDEMIOLOGY; HEALTH; IMMUNOLOGY; WHOOPING COUGH;

BORDETELLA PERTUSSIS; GLOBAL HEALTH; HUMANS; PERTUSSIS VACCINE; SEROEPIDEMIOLOGIC STUDIES; WHOOPING COUGH;

EID: 84959490466     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftv050     Document Type: Review

References (110)

1. Aase A, Herstad TK, Merino S, et al. Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway. Clin Vaccine Immunol 2007;14:855-62.
2. Amirthalingam G, Gupta S, Campbell H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill 2013;18:20587.
3. Andersen P. Pertussis and pertussis prophylaxis in Denmark. Eurosurveillance 2002;6:47.
4. Baughman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immun 2004;11:1045-53.
5. Bowden KE, Williams MM, Cassiday PK, et al. Molecular epidemiology of the pertussis epidemic in Washington State in 2012. J Clin Microbiol 2014;52:3549-57.
6. Campbell P, McIntyre P, Quinn H, et al. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One 2012;7:e35874.
7. Caro V, Elomaa A, Brun D, et al. Bordetella pertussis, Finland and France. Emerg Infect Dis 2006;12:987-89.
8. Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis 1996;173:1256-9.
9. CDC. Centers for Disease Control and Prevention. Pertussis surveillance & reporting 2014. Atlanta, USA, 2015.
10. Chiappini E, Stival A, Galli L, et al. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013;13:151-2334-13-151.
11. Conde-Glez C, Lazcano-Ponce E, Rojas R, et al. Seroprevalence of Bordetella pertussis in the Mexican population: a crosssectional study. Epidemiol Infect 2014;142:706-13.
12. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 2003;88:802-6.
13. Dakic G, Kallonen T, Elomaa A, et al. Bordetella pertussis vaccine strains and circulating isolates in Serbia. Vaccine 2010;28:1188-92.
14. Dalby T, Harboe ZB, Krogfelt KA. Seroprevalence of pertussis among Danish patients with cough of unknown etiology. Clin Vaccine Immunol 2010;17:2016-23.
15. Dashti AS, Karimi A, Arjmand R, et al. Serologic evidence of pertussis infection in vaccinated Iranian children. Iran J Med Sci 2012;37:260-65.
16. de Greeff SC, de Melker HE, van Gageldonk PG, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 2010;5:e14183.
17. de Melker HE, Versteegh FG, Schellekens JF, et al. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006;53:106-13.
18. de Voer RM, van der Klis FR, Nooitgedagt JE, et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis 2009;49:58-64.
19. Diez-Domingo J, Ballester A, Baldo JM, et al. Incidence of pertussis in persons < or = 15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults. J Infect 2004;49:242-7.
20. Dilli D, Bostanci I, Dallar Y, et al. Recent findings on pertussis epidemiology in Turkey. Eur J Clin Microbiol 2008;27:335-41.
21. Dominguez A, Vidal J, Plans P, et al. The seroepidemiology of B. pertussis infection in Catalonia, Spain. Epidemiol Infect 2001;126:205-10.
22. ECDC. Guidance and protocol for the serological diagnosis of human infection with Bordetella pertussis As part of the EUpert-Labnet surveillance network European Center for Disease Control and Prevention (ECDC) Technical document. Stockholm, Sweden, 2012.
23. ECDC. External quality assurance scheme for Bordetella pertussis serology as part of the EUpert-Labnet surveillance network. Stockholm, Sweden, 2013.
24. Elomaa A, He Q, Minh NN, et al. Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine 2009;27:5443-449.
25. Ercan TE, Sonmez C, Vural M, et al. Seroprevalance of pertussis antibodies in maternal and cord blood of preterm and term infants. Vaccine 2013;31:4172-6.
26. Esen B, Coplu N, Kurtoglu D, et al. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. J Clin Lab Anal 2007;21: 154-61.
27. Fallo A, Manonelles G, Hozbor D, et al. Pertussis seroprevalence in adults, post-partumwomen and umbilical cord blood. Arch Argent Pediatr 2014;112:315-22.
28. Forsyth K, Plotkin S, Tan T, et al. Strategies to decrease pertussis transmission to infants. Pediatrics 2015;135:e1475-82.
29. Gaayeb L, Sarr JB, Ndiath MO, et al. Seroprevalence of pertussis in Senegal: a prospective study. PLoS One 2012;7:e48684.
30. Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health 2012;9:4626-38.
31. Gabutti G, Bergamini M, Bonanni P, et al. Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy. Epidemiol Infect 2008;136:1576-84.
32. Garcia-Corbeira P, Dal-Re R, Aguilar L, et al. Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study. Vaccine 2000;18:2173-6.
33. Ghanaie RM, Karimi A, Sadeghi H, et al. Sensitivity and specificity of the World Health Organization pertussis clinical case definition. Int J Infect Dis 2010;14:e1072-5.
34. Giammanco A, Chiarini A, Maple PA, et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003;22:112-20.
35. Grgic-Vitek M, Klavs I, Kraigher A. Re-emergence of pertussis in Slovenia: time to change immunization policy. Vaccine 2008;26:1874-78.
36. Guiso N. Bordetella pertussis: Why is it still circulating? J Infect 2013a;68(Suppl 1):S119-24.
37. Guiso N. How to fight pertussis? Ther Adv Vaccines 2013b;1:59-66.
38. Guiso N, Berbers G, Fry NK, et al. EU Pertstrain group. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol 2011;30:307-12.
39. Hallander HO. Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999;28(Suppl 2):S99-106.
40. Hallander HO, Andersson M, Gustafsson L, et al. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS 2009;117:912-22.
41. Hara M, Fukuoka M, Tashiro K, et al. Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in Japan. BMC Infect Dis 2015;15:45-015-0777-3.
42. Hashemi SH, Ranjbar M, Hajilooi M, et al. Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study. BMC Infect Dis 2009;9:58-2334-9-58.
43. He Q, Barkoff AM, Mertsola J, et al. High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. Euro Surveill 2012;17:20239.
44. Hellenbrand W, Beier D, Jensen E, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis 2009;9: 22-2334-9-22.
45. Hendrikx LH, Schure RM, Ozturk K, et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine 2011;29:6874-80.
46. Hewlett EL, Edwards KM. Clinical practice. Pertussis-not just for kids. New Engl J Med 2005;352:1215-22.
47. Hodder SL, Cherry JD, Mortimer EA, Jr, et al. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis 2000;31:7-14.
48. Huygen K, Rodeghiero C, Govaerts D, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012. Epidemiol Infect 2013;142:724-8.
49. Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996;14:359-68.
50. Jogi P, Oona M, Toompere K, et al. Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia. Vaccine 2014;32:5311-5.
51. Kapasi A, Meade BD, Plikaytis B, et al. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays. Clin Vaccine Immunol 2012;19:64-72.
52. Kennerknecht N, Riffelmann M, Schmetz J, et al. Comparison of commercially available immunoblot assays measuring IgG and IgA antibodies to Bordetella pertussis antigens. Eur J Clin Microbiol 2011;30:1531-5.
53. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. New Engl J Med 2012;367:1012-9.
54. Konda T, Kamachi K, Iwaki M, et al. Distribution of pertussis antibodies among different age groups in Japan. Vaccine 2002;20:1711-7.
55. Kosters K, Riffelmann M, Dohrn B, et al. Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Clin Diagn Lab Immun 2000;7:422-6.
56. Lasserre A, Laurent E, Turbelin C, et al. Pertussis incidence among adolescents and adults surveyed in general practices in the Paris area, France, May 2008 to March 2009. Euro Surveill 2011;16:19783.
57. Launay O, Toneatti C, Bernede C, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccine 2009;5:341-6.
58. Lavine JS, Bjornstad ON, de Blasio BF, et al. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine 2012;30:544-51.
59. Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004;190:535-44.
60. Lee SY, Han SB, Bae EY, et al. Pertussis seroprevalence in korean adolescents and adults using anti-pertussis toxin immunoglobulin G. J Korean Med Sci 2014;29:652-6.
61. Mahmood K, Pelkowski S, Atherly D, et al. Hexavalent IPVbased combination vaccines for public-sector markets of low-resource countries. Hum Vaccine Immunother 2013;9:1894-902.
62. McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015;135: 331-43.
63. NNDSS. Australian Government Department of Health and Ageing National Notifiable Diseases Surveillance System (NNDSS). Canberra, Australia, 2015.
64. Nooitgedagt JE, de Greeff SC, Elvers BH, et al. Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin. Clin Infect Dis 2009;49:1086-9.
65. Okada K, Ueda K, Morokuma K, et al. Comparison of antibody titers in eleven-to twelve-year old Japanese school children six years after administration of acellular and whole cell pertussis vaccines combined with diphtheria-tetanus toxoids. Pediatr Infect Dis J 1998;17:1167-9.
66. Pavlopoulou ID, Syriopoulou V, Daikos GL, et al. Pertussis seroprevalence in different age groups in Greece. Scand J Infect Dis 2007;39:14-8.
67. Pebody RG, Gay NJ, Giammanco A, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 2005;133:159-71.
68. Pourakbari B, Moradi B, Mirzaee F, et al. Seroprevalence of antibodies to diphtheria, tetanus and pertussis among healthy adolescents and adults in Iran Roum. Arch Microbiol Immunol 2013;72:250-4.
69. Preziosi MP, Yam A, Wassilak SG, et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol 2002;155:891-6.
70. Quinn HE, McIntyre PB, Backhouse JL, et al. The utility of seroepidemiology for tracking trends in pertussis infection. Epidemiol Infect 2010;138:426-33.
71. Quinn HE, Mahajan D, Hueston L, et al. The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules. N S W Public Health Bull 2011;22:224-9.
72. Rendi-Wagner P, Tobias J, Moerman L, et al. The seroepidemiology of Bordetella pertussis in Israel-Estimate of incidence of infection. Vaccine 2010;28:3285-90.
73. Riffelmann M, Thiel K, Schmetz J, et al. Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. J Clin Microbiol 2010;48:4459-63.
74. Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis-Ohio, 2010-2011. Clin Infect Dis 2013;56:322-31.
75. Ronn PF, Dalby T, Simonsen J, et al. Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark. Epidemiol Infect 2014;142:729-37.
76. Rota MC, D'Ancona F, Massari M, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005;23:5299-305.
77. Sato H, Sato Y. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan. Clin Infect Dis 1999;28(suppl 2):S124-30.
78. Scott S, Odutola A, Mackenzie G, et al. Coverage and timing of children's vaccination: an evaluation of the expanded programme on immunisation in The Gambia. PLoS One 2014;9:e107280.
79. Scott S, van der Sande M, Faye-Joof T, et al. Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates. Pediatr Infect Dis J 2015;34:333-8.
80. Sealey KL, Harris SR, Fry NK, et al. Genomic analysis of isolates from the UK 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving. J Infect Dis 2014;212:294-301.
81. Sedighi I, Rahimi H, Emadoleslami M, et al. Seroepidemiology of bordetella pertussis infection in fresh college students in Iran: a multicenter study. Arch Clin Infect Dis 2014;9: e17922.
82. Shakib JH, Ralston S, Raissy HH, et al. Pertussis antibodies in postpartum women and their newborns. J Perinatol 2010;30:93-7.
83. Sheridan SL, Frith K, Snelling TL, et al. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines 2014;13:1081-106.
84. Sizaire V, Garrido-Estepa M, Masa-Calles J, et al. Increase of pertussis incidence in 2010 to 2012 after 12 years of low circulation in Spain. Euro Surveill 2014;19:20875.
85. Socan M, Prosenc K, Vegnuti M. Seroprevalence of IgG antibodies to pertussis toxin in the Slovene population. Wien Klin Wochenschr 2006;118:336-40.
86. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001;183:1353-9.
87. Theodoridou M, Dargenta G, Aptouramani M, et al. Pertussis epidemiology in greece and emerging risk groups during the vaccination era (1980-2008). Adv Prev Med 2012;2012:303846.
88. Therre H, Baron S. Pertussis immunisation in Europe - the situation in late 1999. Euro Surveill 2000;5:6-10.
89. Thomas MG, Ashworth LA, Miller E, et al. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J Infect Dis 1989;160:838-45.
90. Torm S, Meriste S, Tamm E, et al. Pertussis outbreak in a basic school in Estonia: description, contributing factors and vaccine effectiveness. Scand J Infect Dis 2005;37:664-68.
91. van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008;335:79-89.
92. Vatansever U, Coplu N, Oner N, et al. Seroprevalance of Bordetella pertussis antibodies among healthy adolescent girls in Edirne. Swiss Med Wkly 2005;135:531-6.
93. Wang CQ, Zhu QR. Seroprevalence of Bordetella pertussis antibody in children and adolescents in China. Pediatr Infect Dis J 2011;30:593-6.
94. Ward JI, Cherry JD, Chang SJ, et al. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis 2006;43: 151-7.
95. Watanabe M, Nagai M. Acellular pertussis vaccines in Japan: past, present and future. Expert Rev Vaccines 2005;4: 173-84.
96. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24:S58-61.
97. WHO (World Health Organization). CISID database 2015., 2015.
98. WHO. Global immunization data, 2014a. http://www.who.int/immunization/monitoring surveillance/global immunizationdata.pdf?ua=1 (31 July 2015, date last accessed).
99. WHO. Weekly epidemiological record. 2014b;89:221. http://www.who.int/wer/2014/wer8921.pdf?ua=1 (31 July 2015, date last accessed).
100. WHO. The immunological basis for immunization seriesmodule 4: Pertussis Update 2009. 2010.
101. Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr 2012;161:1091-6.
102. Wu Y, Zhu B, Gao Y, et al. Clustered cases of Bordetella pertussis infection cause high levels of IgG antibodies against pertussis toxin in adolescents in Gaobeidian city, China. Epidemiol Infect 2014;142:738-43.
103. Xing D, Markey K, Newland P, et al. EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis. J Immunol Methods 2011;372: 137-45.
104. Xing D, Wirsing von Konig CH, Newland P, et al. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin Vaccine Immunol 2009;16:303-11.
105. Xu Y, Wang L, Xu J, et al. Seroprevalence of pertussis in China: need to improve vaccination strategies. Hum Vaccine Immunother 2014;10:192-8.
106. Zawadka M, Mosiej E, Polak M, et al. Consistency of Bordetella pertussis vaccine seed strains and potency of whole-cell pertussis vaccine still in use in Poland. Biologicals 2014;42: 123-7.
107. Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11:557-70.
108. Zhang L, Xu Y, Zhao J, et al. Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis 2010;16:1695-1701.
109. Zhang Q, Han F, Nie Q, et al. Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China. J Infect 2011;63:441-6.
110. Zhang Q, Zheng H, Liu M, et al. The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. BMC Infect Dis 2012;12:138.